Condition: Head and Neck Cancer · Oral Cavity Cancer · Oropharynx Cancer · Sponsor: Institut Claudius Regaud
This is a phase 1b, multicenter, non-randomized prospective study involving an innovation phase (IDEAL-1) followed by a prospective development phase (IDEAL-2A) designed to evaluate the safety and feasibility of oral/oropharyngeal reconstruction with the external pudendal free flap in two groups of patients. A maximum of 40 patients (20 patients per group) will be included in this IDEAL-1/2A phase study. Stage IDEAL-1: Innovation phase. The main objective is to evaluate the feasibility in terms of limiting surgical complications of a STEPA flap reconstruction in two groups of patients (Cohort: Male, Female). Stage IDEAL-2A: Prospective development phase. The main objective is to describe the complication profile of the surgical procedure in these two patient populations. Each patient will be followed during 12 months after the end of complete treatment (surgery ± adjuvant treatment). A complementary study (observational study) of 250 patients will also be conducted to evaluate the acceptability of the technique (reconstruction by external pudendal flap) by the patients and to describe the factors associated with this acceptability.
This description comes directly from the study's public registry record.
Agnès DUPRET-BORIES · 05 31 15 53 08 · dupret-bories.agnes@iuct-oncopole.fr
Always discuss trial participation with your own doctor first.
| Chu Gui de Chauliac | Montpellier, France | Not Yet Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Chu Purpan | Toulouse, France | Not Yet Recruiting |
| Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O) | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05757817